Elvina Almuradova· @Dr_ElvinaA · X·· 13 小时前评分70
正文 · 机器翻译
#ESMO26 | DeLLphi-305
维持治疗 tarlatamab + durvalumab 将 ES-SCLC 的中位 OS 延长至 21.1 个月，而 durvalumab 单药组为 12.7 个月；预设中期分析 @NEJM @myESMO @Larvol
65 浏览 · 3 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Elvina Almuradova · x.com